NO944838L - Arabinogalactan derivatives and uses thereof - Google Patents

Arabinogalactan derivatives and uses thereof

Info

Publication number
NO944838L
NO944838L NO944838A NO944838A NO944838L NO 944838 L NO944838 L NO 944838L NO 944838 A NO944838 A NO 944838A NO 944838 A NO944838 A NO 944838A NO 944838 L NO944838 L NO 944838L
Authority
NO
Norway
Prior art keywords
derivative
cell receptor
arabinogalactan
arabinogalactan derivatives
derivatives
Prior art date
Application number
NO944838A
Other languages
Norwegian (no)
Other versions
NO944838D0 (en
Inventor
Chu Jung
Philip Enriques
Stephen Palmacci
Lee Josephson
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Publication of NO944838D0 publication Critical patent/NO944838D0/en
Publication of NO944838L publication Critical patent/NO944838L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Det tilveiebringes en bærer for å danne et kompleks med et terapeutisk middel for tilførsel derav til en cellereseptor som er lokalisert på overflaten av et targetvev omfattende: arabinogalaktan modifisert ved et sted av en funksjonell rest for å fremstille et derivat på en måte som bevarer den nyttige affiniteten av derivatet for cellereseptoren, og komplekser derav.A carrier is provided to form a complex with a therapeutic agent for delivery thereof to a cell receptor located on the surface of a target tissue comprising: arabinogalactan modified at a site of a functional residue to prepare a derivative in a manner that retains the useful the affinity of the derivative for the cell receptor, and complexes thereof.

NO944838A 1992-06-17 1994-12-14 Arabinogalactan derivatives and uses thereof NO944838L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/005091 WO1993025239A1 (en) 1992-06-17 1992-06-17 Arabinogalactan derivatives and uses thereof

Publications (2)

Publication Number Publication Date
NO944838D0 NO944838D0 (en) 1994-12-14
NO944838L true NO944838L (en) 1995-02-17

Family

ID=4154623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944838A NO944838L (en) 1992-06-17 1994-12-14 Arabinogalactan derivatives and uses thereof

Country Status (5)

Country Link
EP (1) EP0646018A1 (en)
JP (1) JPH07507794A (en)
CA (1) CA2135295A1 (en)
NO (1) NO944838L (en)
WO (1) WO1993025239A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
FR2716625B1 (en) * 1994-02-25 1996-04-26 Gouchet Franck Arno Preparation and use of pharmaceutical and cosmetic forms containing inclusion compounds with cysteamine cyclodextrins, cysteamine salts, or cysteamine derivatives, in salt form or not.
US5567685A (en) * 1994-08-16 1996-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Water-Soluble polyene conjugate
US5897987A (en) 1996-03-25 1999-04-27 Advanced Reproduction Technologies, Inc. Use of arabinogalactan in cell cryopreservation media
US6303584B1 (en) * 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
ATE466948T1 (en) 1997-03-11 2010-05-15 Univ Minnesota DNA-BASED TRANSPOSON SYSTEM FOR INTRODUCING NUCLIC ACID INTO A CELL'S DNA
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
WO1999055736A2 (en) * 1998-04-27 1999-11-04 Larex, Inc. Derivatives of arabinogalactan and compositions including the same
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
WO2001089579A2 (en) * 2000-05-19 2001-11-29 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
ITMI20040928A1 (en) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D PROCEDURE FOR THE PREPARATION OF DOXORUBICIN CONJUGATES WITH LACTOSAMINATED HUMAN ALBUMIN
ITMI20051743A1 (en) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa USE OF DOXORUBICINE CONJUGIES WITH LATTOSAMINATED ALBUMIN
RU2359975C2 (en) * 2007-04-04 2009-06-27 Институт нефтехимии и катализа РАН Method for production of modified arabinogalactan
CN102399238B (en) * 2011-12-21 2013-06-12 开封明仁药业有限公司 Preparation method for amifostine
RU2521649C1 (en) * 2013-03-04 2014-07-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Химии И Химической Технологии Сибирского Отделения Российской Академии Наук (Иххт Со Ран) Method of producing sulphated arabinogalactan derivatives
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3250023T (en) * 1981-01-14 1990-03-29
JPH0816118B2 (en) * 1988-02-03 1996-02-21 呉羽化学工業株式会社 Antiviral agent
ATE139431T1 (en) * 1988-08-04 1996-07-15 Advanced Magnetics Inc RECEPTOR-INDUCED CONTRAST AGENT FOR ENDOCYTOSIS TYPE MRI

Also Published As

Publication number Publication date
EP0646018A1 (en) 1995-04-05
JPH07507794A (en) 1995-08-31
CA2135295A1 (en) 1993-12-23
WO1993025239A1 (en) 1993-12-23
NO944838D0 (en) 1994-12-14

Similar Documents

Publication Publication Date Title
NO944838L (en) Arabinogalactan derivatives and uses thereof
NO985975L (en) Mixtures and Methods for Producing Pharmacologically Active Preparations and Uses thereof
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
DK0655916T3 (en) Agent for transdermal administration containing 3-ketodesogestrel
ATE219765T1 (en) INDOLE DERIVATIVES AS CGMP-PDE INHIBITORS
NO308794B1 (en) Pharmacologically active pyridine derivatives, preparations containing the compounds and the use of the compounds
MX9702382A (en) New pyrimidone derivatives with antifungal activity.
EP0943328A3 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
PT946191E (en) USE OF GLP-1 ANALOGUES AND DERIVATIVES ADMINISTERED UNDERLYING IN THE ADJUSTMENT OF OBESITY
TR199901417T2 (en) New compositions with analgesic effect.
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
FI954944A7 (en) Indole derivatives as 5-HT1-like agonists for use in the treatment of migraine
LV10183A (en) Perorala composition for the treatment of inflammatory bowel disease
KR950700749A (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
FI931765A7 (en) Steroid derivatives for the treatment of benign prostatic hyperplasia, their preparation and uses
DE69021501D1 (en) ANTI-INFLAMMATORY 4-AMINOPHENOL DERIVATIVES.
AU2740797A (en) Androstene derivatives
DE69826684D1 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
DE69404116D1 (en) Pharmaceutical dosage unit coated with sugar
MX9706605A (en) Indole derivatives as eaa antagonists.
DK158358C (en) 1-SUBSTITUTED ANDROSTA-1,4-DIEN-3,17-DIONES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE69612056D1 (en) TERPEN DERIVATIVES (SARCODICTYINE) AS AN ANTICRECELLENT
IL131478A0 (en) Methods for treatment of scar tissue
GR3017967T3 (en) Substituted pyrido-oxazines.